http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2061461-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 |
| filingDate | 2007-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6302b7bf4bd9c5e1490cb590114d2943 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43cbc2852e7a503d967a0b2e3969174d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_627ef1925ee8dfed3b4bf94951eaf81a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a4764ecb22cbf3aa7022ed6ee491225 |
| publicationDate | 2009-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2061461-A2 |
| titleOfInvention | 3-azabicyclo[4.1.0]heptane derivatives for the treatment of depression |
| abstract | The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof: formula (I), wherein G is selected from a group consisting of: phenyl, a 5- or 6-membered monocyclic heteroaryl group, or a 8- to 11-membered heteroaryl bicyclic group; such G may be substituted by (R2)p, which can be the same or different; R1 is hydrogen or C1-4alkyl; R2 is halogen, hydroxy, cyano,C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to R8; R5 is hydrogen or C1-4 alkyl; R6 is hydrogen or C1-4 alkyl; R7 is selected in the group consisting of: hydrogen, fluorine, and C1-4 alkyl; or corresponds to X, X1, X2 or X3; wherein X corresponds to: formula (a) X1 corresponds to: formula (b) X2 corresponds to: formula (c) X3 corresponds to: formula (d) R3 is hydrogen or C1-4 alkyl; or corresponds to X or X1; R4 is hydrogen or C1-4 alkyl; or corresponds to X or X1; R8 is a 5-6 membered heterocycle group, which may be substituted by one or two substituents selected from a group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy and C1-4alkanoyl; R9 is C1-4alkyl; R10 is hydrogen, C1-4alkyl, C3-6cycloalkyl or C3-6cycloalkylC1-3alkyl; R11 is haloC1-2alkyl; p is an integer from 0 to 5; n is 1 or 2. processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as as serotonin (5-HT), dopamine (DA) and norepinephrine (NE), re-uptake inhibitors. |
| priorityDate | 2006-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 760.